top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-L1 low MC38
Common name
B-hPD-L1 low MC38 Catalog number    310889
Aliases CD274, PDCD1L1 Disease  Colon carcinoma
Organism
Mouse
Strain  C57BL/6
Tissue types Colon Tissue  Colon

Description


The mouse Pdl1  gene was replaced by human PD-L1 coding sequence in B-hPD-L1 low MC38 cells. Human PD-L1 is expressed on the surface of B-hPD-L1 low MC38 cells.


Application


B-hPD-L1 low MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.


Targeting strategy

Gene targeting strategy for B-hPD-L1 low MC38 cells. The exogenous promoter and human PD-L1 coding sequence was inserted to replace part of murine exon 3. The insertion disrupts the endogenous murine Pdl1 gene, resulting in a non-functional transcript.

Protein expression analysis 

from clipboard


PD-L1 expression analysis in B-hPD-L1 low MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38, B-hPD-L1 MC38 plus and B-hPD-L1 low MC38 cultures were stained with species-specific anti-PD-L1 antibody. Mouse PD-L1 was detectable in wild-type MC38 cells. Human PD-L1 was detectable in B-hPD-L1 low MC38 cells, and human PD-L1 was expressed highly on the surface of B-hPD-L1 MC38 plus cells. The 2-C09 clone of B-hPD-L1 low MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hPD-L1 low MC38 cells. B-hPD-L1 low MC38 cells (1x106) and wild-type MC38 cells (1x106) were subcutaneously implanted into C57BL/6 mice (female, 6-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hPD-L1 low MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.
The subcutaneous tumor formation of B-hPD-L1 low MC38 cells was slow, and the inoculation dose was recommended to be increased to 1x106.

In vivo efficacy of anti-human PD-1 antibody

from clipboard


Antitumor activity of anti-human PD-1 antibody (pembrolizumab, in house) in B-hPD-1/hPD-L1 mice. (A) Anti-human PD-1 antibody inhibited MC38 tumor growth in B-hPD-1/hPD-L1 mice. Murine colon cancer B-hPD-L1 low MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice (female, 7-week-old, n=6). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with anti-human PD-1 antibody indicated in panel. (B) Body weight changes during treatment. (C) TILs analysis from tumor tissue. Results showed that anti-human PD-1 antibody was efficacious in controlling tumor growth in B-hPD-1/hPD-L1 mice, demonstrating that the B-hPD-1/hPD-L1 mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-1 antibodies. Values are expressed as mean ± SEM.